fluconazole has been researched along with Kidney Diseases in 33 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The fungal infection was successfully controlled using fluconazole, and the patient has been disease-free for more than 11 months after antileukemic chemotherapy without any recurrence of Candida infections." | 7.71 | Successful treatment of hepatosplenic candidiasis in an elderly patient with acute myeloid leukemia using liposomal daunorubicin and fluconazole. ( Barbera, V; Gambino, R; Mariani, G; Minardi, V; Quintini, G; Spadola, V, 2001) |
| "The bis triazole agent fluconazole is used widely in the treatment of superficial and deep mycoses." | 7.69 | Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. ( Debruyne, D, 1997) |
| "Fluconazole (FLU) is a new antifungal agent that has been used successfully to treat Candida infections and has modest activity against aspergillosis in animal models." | 6.67 | Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. ( Anaissie, EJ; Bodey, GP; Elting, LS; Estey, E; Kantarjian, H; O'Brien, S, 1994) |
| " Fluconazole clearance was dependent on creatinine clearance, and volume of distribution was dependent on body weight and age." | 5.10 | Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit. ( Hendrix, CW; Lipsett, PA; Pelz, RK; Rajagopalan, P; Rinaldi, MG; Swoboda, SM, 2003) |
| " We report on a patient with sepsis and renal fungal ball who was treated with percutaneous nephrostomy and intravenous antifungal agent, but the patient did not respond so instillation of fluconazole through nephrostomy was given." | 4.98 | Treatment of Renal Fungal Ball with Fluconazole Instillation Through a Nephrostomy Tube: Case Report and Literature Review. ( Abdeljaleel, OA; Ali, O; Alnadhari, I; Khachatryan, G; Mahmoud, S; Salah, M; Shamsodini, A, 2018) |
| " The fungal infection was successfully controlled using fluconazole, and the patient has been disease-free for more than 11 months after antileukemic chemotherapy without any recurrence of Candida infections." | 3.71 | Successful treatment of hepatosplenic candidiasis in an elderly patient with acute myeloid leukemia using liposomal daunorubicin and fluconazole. ( Barbera, V; Gambino, R; Mariani, G; Minardi, V; Quintini, G; Spadola, V, 2001) |
| "Few data exist concerning the combined use of fluconazole systemically and as an irrigant for nephrostomy tubes in a patient with renal candidiasis." | 3.70 | The use of fluconazole as a local irrigant for nephrostomy tubes. ( Clark, MA; Czachor, JS; Gaunt, T, 1999) |
| "The bis triazole agent fluconazole is used widely in the treatment of superficial and deep mycoses." | 3.69 | Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. ( Debruyne, D, 1997) |
| "Fosfluconazole is a phosphate prodrug of fluconazole (FLCZ)." | 2.71 | The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. ( Layton, G; Leclerc, V; Sobue, S; Tan, K; Weil, A, 2004) |
| "Fluconazole (FLU) is a new antifungal agent that has been used successfully to treat Candida infections and has modest activity against aspergillosis in animal models." | 2.67 | Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. ( Anaissie, EJ; Bodey, GP; Elting, LS; Estey, E; Kantarjian, H; O'Brien, S, 1994) |
| "Cryptococcosis is an important opportunistic infection of organ transplant recipients." | 1.48 | Cryptococcoma of a transplanted kidney in a patient presenting with recurrent urinary tract infection: a case report. ( Greeff, L; Karusseit, VOL; Lengano, T; Muranda, AZ; Sathekge, MM, 2018) |
| "Candidiasis is still of major concern in neonates with accompanying risk factors." | 1.38 | Candidiasis caused by Candida kefyr in a neonate: case report. ( Dietz, A; Geginat, G; Kilian, AK; Reinshagen, K; Schroten, H; Tenenbaum, T; Weichert, S; Zahn, K, 2012) |
| " The occurrence of LAMB-attributable renal toxicity was investigated; infants withdrawn from treatment for development of adverse effects or toxicity were identified." | 1.38 | Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates. ( Antonucci, R; Fanos, V; Farina, D; Franco, C; Galletto, P; Gallo, E; Manzoni, P; Rizzollo, S, 2012) |
| "Fluconazole was used in 48% of the treatment episodes, amphotericin B in 46%, itraconazole in 4." | 1.34 | Drug-drug interactions with systemic antifungals in clinical practice. ( Abouelfath, A; Depont, F; Dupon, M; Dutronc, H; Galpérine, T; Giauque, E; Hébert, G; Moore, N; Ragnaud, JM; Valentino, R; Vargas, F, 2007) |
| "A 47-year-old man with diabetic nephropathy and alcoholic liver disease developed disseminated candidiasis, with the initial presentation of pyomyositis." | 1.33 | Pyomyositis with hepatic and perinephric abscesses caused by Candida albicans in a diabetic nephropathy patient. ( Peng, YJ; Tsai, SH; Wang, NC, 2006) |
| "This syndrome has a favorable prognosis." | 1.29 | A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. ( Hussein, A; Meisenberg, B; Mudad, R; Paulson, EK; Peters, WP; Ross, M; Vredenburgh, J, 1994) |
| "Fluconazole is an antifungal agent available for oral and parenteral use." | 1.29 | Fluconazole dosing in renal impairment: a drug usage evaluation. ( Moody, SB; Sveska, KJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 12 (36.36) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 8 (24.24) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Rodríguez Arias, EA | 1 |
| Santoya Espinosa, LC | 1 |
| Romano, JP | 1 |
| Mota, MF | 1 |
| Chabay, P | 1 |
| Diaz Aguiar, P | 1 |
| Yetmar, ZA | 1 |
| Cano Cevallos, E | 1 |
| Pritt, B | 1 |
| DeSimone, DC | 1 |
| Muranda, AZ | 1 |
| Greeff, L | 1 |
| Sathekge, MM | 1 |
| Lengano, T | 1 |
| Karusseit, VOL | 1 |
| Ray, S | 1 |
| Shankar, S | 1 |
| Abdeljaleel, OA | 1 |
| Alnadhari, I | 1 |
| Mahmoud, S | 1 |
| Khachatryan, G | 1 |
| Salah, M | 1 |
| Ali, O | 1 |
| Shamsodini, A | 1 |
| Póvoa, P | 1 |
| Gonçalves-Pereira, J | 1 |
| Vinekar, A | 1 |
| Avadhani, K | 1 |
| Maralusiddappa, P | 1 |
| Prabhu, VM | 1 |
| Mahendradas, P | 1 |
| Indumathi, VA | 1 |
| Weichert, S | 1 |
| Reinshagen, K | 1 |
| Zahn, K | 1 |
| Geginat, G | 1 |
| Dietz, A | 1 |
| Kilian, AK | 1 |
| Schroten, H | 1 |
| Tenenbaum, T | 1 |
| Manzoni, P | 1 |
| Galletto, P | 1 |
| Rizzollo, S | 1 |
| Franco, C | 1 |
| Gallo, E | 1 |
| Antonucci, R | 1 |
| Fanos, V | 1 |
| Farina, D | 1 |
| Logan, BR | 1 |
| Zhang, MJ | 1 |
| Nasr, SH | 1 |
| Koscica, J | 1 |
| Markowitz, GS | 1 |
| D'Agati, VD | 1 |
| Rajagopalan, P | 1 |
| Pelz, RK | 1 |
| Lipsett, PA | 1 |
| Swoboda, SM | 1 |
| Rinaldi, MG | 1 |
| Hendrix, CW | 1 |
| Sobue, S | 1 |
| Tan, K | 1 |
| Layton, G | 1 |
| Leclerc, V | 1 |
| Weil, A | 1 |
| Tsai, SH | 1 |
| Peng, YJ | 1 |
| Wang, NC | 1 |
| Upton, A | 1 |
| McCune, JS | 1 |
| Kirby, KA | 1 |
| Leisenring, W | 1 |
| McDonald, G | 1 |
| Batchelder, A | 1 |
| Marr, KA | 1 |
| Depont, F | 1 |
| Vargas, F | 1 |
| Dutronc, H | 1 |
| Giauque, E | 1 |
| Ragnaud, JM | 1 |
| Galpérine, T | 1 |
| Abouelfath, A | 1 |
| Valentino, R | 1 |
| Dupon, M | 1 |
| Hébert, G | 1 |
| Moore, N | 1 |
| Lupetti, A | 1 |
| Brouwer, CP | 1 |
| Bogaards, SJ | 1 |
| Welling, MM | 1 |
| de Heer, E | 1 |
| Campa, M | 1 |
| van Dissel, JT | 1 |
| Friesen, RH | 1 |
| Nibbering, PH | 1 |
| Mudad, R | 1 |
| Vredenburgh, J | 1 |
| Paulson, EK | 1 |
| Ross, M | 1 |
| Meisenberg, B | 1 |
| Hussein, A | 1 |
| Peters, WP | 1 |
| Montalvo, JA | 1 |
| Montaner, A | 1 |
| Torino, JR | 1 |
| Ribó, JM | 1 |
| Morales, L | 1 |
| Weintrub, PS | 1 |
| Chapman, A | 1 |
| Piecuch, R | 1 |
| Krcméry, V | 1 |
| Trupl, J | 1 |
| Krídl, J | 1 |
| Danisovicová, A | 1 |
| Bodey, GP | 1 |
| Anaissie, EJ | 1 |
| Elting, LS | 1 |
| Estey, E | 1 |
| O'Brien, S | 1 |
| Kantarjian, H | 1 |
| Debruyne, D | 1 |
| Hershman-Sarafov, M | 1 |
| Tubi, O | 1 |
| Srugo, I | 1 |
| Bader, D | 1 |
| Aktug, T | 1 |
| Olguner, M | 1 |
| Akgür, FM | 1 |
| Aldirmaz, C | 1 |
| Hoşgör, M | 1 |
| Yulug, N | 1 |
| Clark, MA | 1 |
| Gaunt, T | 1 |
| Czachor, JS | 1 |
| Moody, SB | 1 |
| Sveska, KJ | 1 |
| Stocker, M | 1 |
| Caduff, JH | 1 |
| Spalinger, J | 1 |
| Berger, TM | 1 |
| Quintini, G | 1 |
| Barbera, V | 1 |
| Gambino, R | 1 |
| Spadola, V | 1 |
| Minardi, V | 1 |
| Mariani, G | 1 |
| Chung, BH | 1 |
| Chang, SY | 1 |
| Kim, SI | 1 |
| Choi, HS | 1 |
| Dudley, MN | 1 |
| Dave, J | 1 |
| Hickey, MM | 1 |
| Wilkins, EG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia[NCT01615809] | Phase 2 | 32 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence of invasive pulmonary aspergillosis during the Abelcet® prophylactic treatment period was assessed by the relation between the number of patients with invasive pulmonary aspergillosis and the number of paediatric patients on prophylaxis with Acute Leukaemia (AL) undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 3 |
Percentage of deaths related to Invasive Pulmonary Aspergillosis during the prophylactic treatment period with Abelcet® in paediatric patients with Acute Leukaemia undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | percentage of deaths (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
is assessed by the proportion of patients who discontinue prophylactic treatment with Abelcet® due to an adverse event that is related or not to the study drug or for intolerability to it. The last week of treatment will have a different calendar for each participant, depending on the number of cicles needed by each patient (it has been anticipated up to 5 cicles of 2-6 weeks each). (NCT01615809)
Timeframe: at the Baseline visit (week 1) and during the Last week of treatment, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
3 reviews available for fluconazole and Kidney Diseases
| Article | Year |
|---|---|
Treatment of Renal Fungal Ball with Fluconazole Instillation Through a Nephrostomy Tube: Case Report and Literature Review.
Topics: Administration, Topical; Antifungal Agents; Candida albicans; Candidiasis; Diabetes Complications; F | 2018 |
Treatment of candidemia in adult patients without neutropenia--an inconvenient truth.
Topics: Adult; Amphotericin B; Animals; Antifungal Agents; Candidemia; Echinocandins; Fluconazole; Fungal Pr | 2011 |
Clinical pharmacology of fluconazole.
Topics: Absorption; Aging; Bone Marrow Transplantation; Fluconazole; Humans; Kidney Diseases; Molecular Stru | 1990 |
4 trials available for fluconazole and Kidney Diseases
| Article | Year |
|---|---|
Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antifungal Agents; Biological Availability; Body Weight | 2003 |
The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Female; Fluconazole; Humans; Injections, Int | 2004 |
Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation.
Topics: Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Chemical and Drug Induced Liver Injury; Cohort Stu | 2007 |
Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Blast Crisis; Female; Flu | 1994 |
26 other studies available for fluconazole and Kidney Diseases
| Article | Year |
|---|---|
[Bilateral multifocal kidney abscess due to Candida albicans].
Topics: Abscess; Adult; Antifungal Agents; Candida albicans; Child; Female; Fluconazole; Humans; Kidney; Kid | 2023 |
Disseminated Blastomycosis Presenting as Obstructive Renal Mass Treated With Fluconazole.
Topics: Aged; Antifungal Agents; Blastomycosis; Constriction, Pathologic; Fluconazole; Humans; Image-Guided | 2020 |
Cryptococcoma of a transplanted kidney in a patient presenting with recurrent urinary tract infection: a case report.
Topics: Adult; Antifungal Agents; Bacterial Infections; Biopsy; Coinfection; Cryptococcosis; Cryptococcus ne | 2018 |
Renal ultrasound imaging in a preterm infant with a persistently elevated C reactive protein.
Topics: Antifungal Agents; C-Reactive Protein; Female; Fluconazole; Humans; Infant, Newborn; Infant, Prematu | 2018 |
Retinal vasculitis as an early indicator of systemic candidal abscesses in a premature infant.
Topics: Abscess; Antifungal Agents; Bacteremia; Candida albicans; Candidiasis; Eye Infections, Fungal; Fluco | 2011 |
Candidiasis caused by Candida kefyr in a neonate: case report.
Topics: Amphotericin B; Antifungal Agents; Anus, Imperforate; Candida; Candidiasis; Congenital Abnormalities | 2012 |
Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Cohort Studies; Creatinine; Fluconazole; Humans; Hyp | 2012 |
The use of group sequential designs with common competing risks tests.
Topics: Blood Platelets; Clinical Trials as Topic; Computer Simulation; Cord Blood Stem Cell Transplantation | 2013 |
Granulomatous interstitial nephritis.
Topics: Anti-Inflammatory Agents; Antifungal Agents; Antigens, Fungal; Diagnosis, Differential; Drug Combina | 2003 |
Pyomyositis with hepatic and perinephric abscesses caused by Candida albicans in a diabetic nephropathy patient.
Topics: Abdominal Abscess; Antifungal Agents; Candida albicans; Candidiasis; Diabetic Nephropathies; Diagnos | 2006 |
Drug-drug interactions with systemic antifungals in clinical practice.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Creatinine; Cyclosporine; Drug Interactions; Female; | 2007 |
Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Carrier Proteins; Dose-Response Relations | 2007 |
A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Mar | 1994 |
[Obstructive candidiasis: a process with surgical solution].
Topics: Adolescent; Amphotericin B; Candidiasis; Fluconazole; Humans; Infant; Infant, Newborn; Intestinal Ob | 1994 |
Renal fungus ball in a premature infant successfully treated with fluconazole.
Topics: Amphotericin B; Candidiasis; Fluconazole; Humans; Infant, Newborn; Infant, Premature; Infant, Premat | 1994 |
Renal abscess and fungemia due to Torulopsis glabrata: successful treatment with drainage and fluconazole.
Topics: Abscess; Adult; Candida; Candidiasis; Combined Modality Therapy; Drainage; Female; Fluconazole; Huma | 1994 |
Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.
Topics: Age Factors; Antifungal Agents; Dose-Response Relationship, Drug; Fluconazole; Humans; Kidney Diseas | 1997 |
Systemic antifungal drugs.
Topics: Amphotericin B; Anorexia; Antifungal Agents; Aspergillosis; Blastomycosis; Candidiasis; Coccidioidom | 1997 |
[Fungus-ball in a preterm infant successfully treated with fluconazole].
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Fluconazole; Humans; Infant, Newborn; Infant, Premat | 1998 |
A new ancient irrigation therapy for childhood renal candidiasis.
Topics: Administration, Oral; Anti-Infective Agents, Urinary; Antifungal Agents; Candidiasis; Female; Flucon | 1998 |
The use of fluconazole as a local irrigant for nephrostomy tubes.
Topics: Adult; Antifungal Agents; Candidiasis; Carcinoma, Squamous Cell; Fatal Outcome; Female; Fluconazole; | 1999 |
Fluconazole dosing in renal impairment: a drug usage evaluation.
Topics: Drug Utilization; Evaluation Studies as Topic; Fluconazole; Forms and Records Control; Hospital Bed | 1993 |
Successful treatment of bilateral renal fungal balls with liposomal amphotericin B and fluconazole in an extremely low birth weight infant.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Drug Therapy, Combination; Fluconazole; Humans; Infa | 2000 |
Successful treatment of hepatosplenic candidiasis in an elderly patient with acute myeloid leukemia using liposomal daunorubicin and fluconazole.
Topics: Antibiotics, Antineoplastic; Antifungal Agents; Antineoplastic Agents; Candidiasis; Daunorubicin; Di | 2001 |
Successfully treated renal fungal ball with continuous irrigation of fluconazole.
Topics: Antifungal Agents; Candidiasis; Fluconazole; Humans; Kidney Diseases; Male; Middle Aged; Radiography | 2001 |
Fluconazole in renal candidosis.
Topics: Antifungal Agents; Candidiasis; Fluconazole; Humans; Kidney Diseases; Male; Middle Aged; Triazoles | 1989 |